Therapeutic vaccines for cancer: an overview of clinical trials

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Nature Reviews Clinical Oncology

• Publication date

  2014-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrclinonc.2014.111PMID 25001465
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Correlation of immune responses and survival in a phase II study of belagenpumatucel-L in non-small cell lung cancer.

  2016cited by this paper
• Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

  2014cited by this paper
• Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial

  2013cited by this paper
• Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion

  2013cited by this paper
• Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients

  2013cited by this paper
• Antigen cross-presentation by dendritic cell subsets: one general or all sergeants?

  2013cited by this paper
• Abstract LB-335: Autologous whole-tumor antigen vaccination in combination with adoptive T cell therapy for patients with recurrent ovarian cancer.

  2013cited by this paper
• Immunological monitoring of anticancer vaccines in clinical trials

  2013cited by this paper
• Chemotherapy ± Cetuximab Modulates Peripheral Immune Responses in Metastatic Colorectal Cancer

  2013cited by this paper
• Potential chemo-sensitization effect of tergenpumatucel-L immunotherapy in treated patients with advanced non-small cell lung cancer (NSCLC).

  2013cited by this paper
• Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).

  2013cited by this paper
• Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

  2013cited by this paper
• Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer

  2013cited by this paper
• Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

  2013cited by this paper
• Vanishing bile duct syndrome arising in a patient with T-cell-rich large B-cell lymphoma.

  2013cited by this paper
• Harnessing the immune system for the treatment of non-small-cell lung cancer.

  2013cited by this paper
• Autologous whole-tumor antigen vaccination in combination with adoptive T cell therapy for patients with recurrent ovarian cancer

  2013cited by this paper
• Colorectal cancer immunotherapy.

  2013cited by this paper
• Prostate cancer vaccines

  2013cited by this paper
• Tumoricidal activity of human dendritic cells

  2013cited by this paper
• A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.

  2013cited by this paper
• Mucosal Imprinting of Vaccine-Induced CD8+ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors

  2013cited by this paper
• Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.

  2013cited by this paper
• Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

  2013cited by this paper
• Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy

  2013cited by this paper
• Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• FMS Kinase Inhibitors: Current Status and Future Prospects

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer

  2013cited by this paper
• Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

  2013cited by this paper
• Cytokine changes in response to radio-/chemotherapeutic treatment in head and neck cancer.

  2013cited by this paper
• Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.

  2013cited by this paper
• Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.

  2013cited by this paper
• Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC).

  2013cited by this paper
• Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients

  2012cited by this paper
• Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

  2012cited by this paper
• The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis

  2012cited by this paper
• Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma.

  2012cited by this paper
• Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study

  2012cited by this paper
• Immunogenic cell death and DAMPs in cancer therapy

  2012cited by this paper
• What are regulatory T cells (Treg) regulating in cancer and why?

  2012cited by this paper
• Dendritic cell-based vaccination in metastatic melanoma patients: Phase II clinical trial

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Trial watch

  2012cited by this paper
• Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients.

  2012cited by this paper
• Correlation of interferon-g (IFN-γ) response with survival in a phase II hyperacute (HAL) immunotherapy trial for non-small cell lung cancer (NSCLC).

  2012cited by this paper
• The secret ally: immunostimulation by anticancer drugs

  2012cited by this paper
• Abstract 2692: An ongoing Phase II trial of an adenovirus/PSA vaccine for prostate cancer

  2012cited by this paper
• Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Exploiting the mutanome for tumor vaccination.

  2012cited by this paper
• Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Tumor Stem Cell Antigens as Consolidative Active Specific Immunotherapy: A Randomized Phase II Trial of Dendritic Cells Versus Tumor Cells in Patients With Metastatic Melanoma

  2012cited by this paper
• Abscopal but desirable

  2012cited by this paper
• Safety and Immunogenicity of Vaccination With MART-1 (26–35, 27L), gp100 (209–217, 210M), and Tyrosinase (368–376, 370D) In Adjuvant With PF-3512676 and GM-CSF In Metastatic Melanoma

  2012cited by this paper
• Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: A single‐arm phase II study

  2012cited by this paper
• Cancer vaccines: should we be targeting patients with less aggressive disease?

  2012cited by this paper
• Clinical trial results of the HER‐2/neu (E75) vaccine to prevent breast cancer recurrence in high‐risk patients

  2012cited by this paper
• Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.

  2011cited by this paper
• gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

  2011cited by this paper
• Randomized Phase II Study of BLP25 Liposome Vaccine (L-BLP25) in Patients with Multiple Myeloma

  2011cited by this paper
• Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• A methodological framework to enhance the clinical success of cancer immunotherapy

  2011cited by this paper
• Long‐term follow‐up of patients with resected pancreatic cancer following vaccination against mutant K‐ras

  2011cited by this paper
• INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer

  2011cited by this paper
• Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.

  2011cited by this paper
• Cancer immunotherapy comes of age

  2011cited by this paper
• Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA.

  2011cited by this paper
• Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial

  2011cited by this paper
• The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?

  2011cited by this paper
• Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.

  2011cited by this paper
• CSF1 expression in nongynecological leiomyosarcoma is associated with increased tumor angiogenesis.

  2011cited by this paper
• Potentiation of a P53-SLP vaccine by cyclophosphamide in ovarian cancer, A single ARM phase II study

  2011cited by this paper
• Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation.

  2011cited by this paper
• Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.

  2011cited by this paper
• CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases

  2011cited by this paper
• Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

  2011cited by this paper
• Potential of CXCR4 antagonists for the treatment of metastatic lung cancer

  2011cited by this paper
• Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia

  2010cited by this paper
• Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

  2010cited by this paper
• Desirable cell death during anticancer chemotherapy

  2010cited by this paper
• Mining the plasma immunopeptidome for cancer peptides as biomarkers and beyond

  2010cited by this paper
• Regulatory (FoxP3+) T-cell Tumor Infiltration Is a Favorable Prognostic Factor in Advanced Colon Cancer Patients Undergoing Chemo or Chemoimmunotherapy

  2010cited by this paper
• PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

  2010cited by this paper
• 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.

  2010cited by this paper
• DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) Elicits Long-term T-cell Responses in Patients With Recurrent Prostate Cancer

  2010cited by this paper
• Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells

  2010cited by this paper
• The Tumor-Immune Microenvironment and Response to Radiation Therapy

  2010cited by this paper
• Enhancing adoptive immunotherapy of cancer

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules

  2010cited by this paper
• Phase II Clinical Trials

  2010cited by this paper
• A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients

  2010cited by this paper
• Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens

  2010cited by this paper
• Heterologous Prime/Boost Immunization With p53-based Vaccines Combined With Toll-like Receptor Stimulation Enhances Tumor Regression

  2010cited by this paper

• De novo protein design: a transformative frontier in clinical protein applications

  2026cites this paper
• Breaking barriers in prostate cancer: the mRNA vaccine breakthrough and what comes next

  2026cites this paper
• Immunotherapy in Melanoma: A Dynamic Frontier in Cancer Treatment

  2026cites this paper
• Hyperbranched polycation-based hierarchical assembles as vaccine carrier for cascaded antigen delivery and enhanced immunity response.

  2026cites this paper
• Antigen-Enriched Tumor-Dendritic Cell Fusion Membrane-Coated Metal-Phenolic Nanovaccine Enables Dual T-Cell Activation for Robust Cancer Immunotherapy.

  2026cites this paper
• Nanoparticles Targeting the Tumor Microenvironment for the Treatment of Osteosarcoma: Recent Progress and Perspectives.

  2026cites this paper
• Recent Advancements In Cancer Vaccine Developments: Novel Approaches.

  2026cites this paper
• Eythrocyte-anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial.

  2026cites this paper
• Neoantigens: new hope for cancer therapy

  2025cites this paper
• Novel therapeutic vaccine development strategies targeting high risk HPV16/18-E6/7 oncoproteins, their immunogenicity, and efficacy associated with cervical intraepithelial neoplasia and cervical cancer: a systematic review

  2025cites this paper
• In Situ Cancer Vaccines: Redefining Immune Activation in the Tumor Microenvironment.

  2025cites this paper
• The application of organoids in investigating immune evasion in the microenvironment of gastric cancer and screening novel drug candidates

  2025cites this paper
• Metformin-based nanomedicines for reprogramming tumor immune microenvironment

  2025cites this paper
• Unravelling the modified T cell receptor through Gen-Next CAR T cell therapy in Glioblastoma: Current status and future challenges.

  2025cites this paper
• Immunotherapy and liver transplantation for hepatocellular carcinoma: Current and future challenges

  2025cites this paper
• Immunotherapeutic efficacy of Th1 stimulatory epitopes derived from Leishmania donovani enolase and triose phosphatase isomerase in experimental visceral leishmaniasis.

  2025cites this paper
• A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma

  2025cites this paper
• Injectable hydrogel-based drug formulation for enhancing tertiary lymphoid structure formation and cancer immunotherapy efficacy.

  2025cites this paper
• Montmorillonite-Based Oral Vaccine for Colorectal Cancer Immunotherapy through Mucosal Immune Activation.

  2025cites this paper
• Beyond the Blood-Brain Barrier: Intranasal Vaccines in Cancer Immunotherapy.

  2025cites this paper
• Advances in Cancer Vaccines for Digestive System Cancers: A Systematic Analysis of Clinical Trials

  2025cites this paper
• Advancing glioblastoma immunotherapy: Molecular pathways and innovative therapeutic strategies.

  2025cites this paper
• Efficacy of Using Dendritic Cells in the Treatment of Prostate Cancer: A Systematic Review

  2025cites this paper
• The Role of Therapeutic Vaccines in Cancer Immunotherapy

  2025cites this paper
• Breaking the barriers in effective and safe toll-like receptor stimulation via nano-immunomodulators for potent cancer immunotherapy.

  2025cites this paper
• Cell membrane nanoparticles in cancer therapy: From basic structure to surface functionalization.

  2025cites this paper
• Tumor Cell‐Derived Antigens for Cancer Immunotherapy

  2025cites this paper
• Ice-pop making inspired photothermal ultra-swelling microneedles to facilitate loading and intradermal vaccination of tumor antigen.

  2025cites this paper
• Advancements in Cancer Treatment: Harnessing the Synergistic Potential of Graphene-Based Nanomaterials in Combination Therapy.

  2025cites this paper
• The Latest Progress and Prospects of Immunotherapy in Cancer Treatment

  2025cites this paper
• Health Technology Assessment of mRNA Vaccines: Clinical, Economic, and Public Health Implications

  2025cites this paper
• A Milestone in the Shift from “Passive Killing” to “Active Immunomodulation” in Cancer Treatment—Progress in Melanoma Vaccine Research

  2025cites this paper
• Harnessing the immune system: Insights into cancer vaccines.

  2025cites this paper
• Recent research progress and clinical status of immunotherapy for colorectal cancer.

  2025cites this paper
• Improved Hypoxic Microenvironment By Nanoformulation For Effective T Cell Therapy In Mice Model

  2025cites this paper
• Eliciting antitumor immunity via therapeutic cancer vaccines

  2025cites this paper
• Immunotherapy for precision medicine in colorectal cancer

  2025cites this paper
• RNA vaccines for cancer: revolutionizing immunization strategies.

  2025cites this paper
• Lymph node delivery of immunogenic dendritic cell exosomes via extended-tip microneedles for cancer prevention.

  2025cites this paper
• Breaking Barriers in CRC Immunotherapy: Cutting-Edge Advances in Personalized Peptide Vaccine Development.

  2025cites this paper
• Using the Cancer Epitope Database and Analysis Resource (CEDAR).

  2025cites this paper
• Targeting tumor immune evasion: the role of PD-L1 siRNA in advancing cancer immunotherapy

  2025cites this paper
• Construction and evaluation of a prognostic model for breast cancer based on aging related genes

  2025cites this paper
• Mesothelin in pancreatic cancer: clinical applications and analytical considerations.

  2025cites this paper
• Ultrasound-responsive nanoparticles: Modulating the tumor microenvironment to advance cancer immunotherapy

  2025cites this paper
• A STING agonist potentiates C1 lipidoid-based mRNA cancer vaccine through promoting TNF-α secretion in vivo.

  2025cites this paper
• Advancement insights in cancer vaccines: mechanisms, types, and clinical applications

  2025cites this paper
• Reduced Cish expression by siRNA knockdown in Natural Killer cells promotes anti-tumor effects against gastric cancer cell lines

  2025cites this paper
• Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy

  2025cites this paper
• Metformin improved a heterologous prime-boost of dual-targeting cancer vaccines to inhibit tumor growth in a melanoma mouse model.

  2024cites this paper
• Systematic pan-cancer analyses of the potential function of the Golgi scaffold protein PAQR3

  2024cites this paper
• Impaired monocyte‐derived dendritic cell phenotype in prostate cancer patients: A phenotypic comparison with healthy donors

  2024cites this paper
• Antigen self-presenting dendrosomes swallowing nanovaccines boost antigens and STING agonists codelivery for cancer immunotherapy.

  2024cites this paper
• Cationic pH-sensitive liposomes as tuberculosis subunit vaccine delivery systems: Effect of liposome composition on cellular innate immune responses.

  2024cites this paper
• Whole-Cell Vaccine Preparation Through Prussian Blue Nanoparticles-Elicited Immunogenic Cell Death and Loading in Gel Microneedles Patches

  2024cites this paper
• Development of NHAcGD2/NHAcGD3 conjugates of bacteriophage MX1 virus-like particles as anticancer vaccines

  2024cites this paper
• Molecular Matchmakers: Bioconjugation Techniques Enhance Prodrug Potency for Immunotherapy.

  2024cites this paper
• Rational design of adjuvants boosts cancer vaccines.

  2024cites this paper
• Respiratory delivered vaccines: Current status and perspectives in rational formulation design

  2024cites this paper
• Immunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines.

  2024cites this paper
• A Microfluidic-Based Sensing Platform for Rapid Quality Control on Target Cells from Bioreactors

  2024cites this paper
• A facile approach to preparing personalized cancer vaccines using iron-based metal organic framework

  2024influential citation
• Developing an erythrocyte‒MHC-I conjugate for cancer treatment

  2024cites this paper
• Unmet needs in cervical cancer – can biological therapies plug the gap?

  2024cites this paper
• Prodrugs of paclitaxel improve in situ photo‐vaccination

  2024cites this paper
• Intestinal Lymphatic Biology, Drug Delivery, and Therapeutics: Current Status and Future Directions

  2024cites this paper
• Cancer Vaccines: Another Aspect to Immunotherapy

  2024cites this paper
• Next-generation cancer vaccines and emerging immunotherapy combinations.

  2024cites this paper
• Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells

  2024cites this paper
• Evaluation of PLGA, lipid-PLGA hybrid nanoparticles, and cationic pH-sensitive liposomes as tuberculosis vaccine delivery systems in a Mycobacterium tuberculosis challenge mouse model - A comparison.

  2024cites this paper
• State-Of-The-Art Advancements on Cancer Vaccines and Biomarkers.

  2024cites this paper
• Metal-organic frameworks-engineered reactive-oxygen catalytic materials: Enzyme-mimicking coordinations, structure evolutions, and biotherapeutic applications

  2024cites this paper
• Core-shell tecto dendrimers co-deliver drug/gene for immunomodulation of macrophages and dendritic cells and checkpoint blockade-promoted breast cancer chemoimmunotherapy

  2024cites this paper
• Cationic pH-sensitive liposome-based subunit tuberculosis vaccine induces protection in mice challenged with Mycobacterium tuberculosis.

  2024cites this paper
• A carrier-free nanovaccine combined with cancer immunotherapy overcomes gemcitabine resistance.

  2024cites this paper
• Gemcitabine Resistant Triple Negative Breast Tumor Derived Mesoporous Silicon Nanovaccine Overcame Drug Resistance

  2024cites this paper
• A polymer nanogel-based therapeutic nanovaccine for prophylaxis and direct treatment of tumors via a full-cycle immunomodulation

  2024cites this paper
• Dendritic Cell-Targeted Nanoparticles Enhance T Cell Activation and Antitumor Immune Responses by Boosting Antigen Presentation and Blocking PD-L1 Pathways.

  2024cites this paper
• Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C

  2024cites this paper
• HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity

  2024cites this paper
• Targeting aging and age-related diseases with vaccines

  2024cites this paper
• Dendritic Cell-Based Immunotherapy: The Importance of Dendritic Cell Migration

  2024cites this paper
• Orchestrated codelivery of peptide antigen and adjuvant to antigen-presenting cells by using an engineered chimeric peptide enhances antitumor T-cell immunity.

  2024cites this paper
• Inosine pranobex-derived coordination complexes for self-adjuvant, self-carrier, and self-assembled vaccines in cancer immunotherapy

  2024cites this paper
• Understanding the Intricacies of Cellular Senescence in Atherosclerosis: Mechanisms and Therapeutic Implications.

  2024cites this paper
• A Cancer Nanovaccine Based on an FeAl-Layered Double Hydroxide Framework for Reactive Oxygen Species-Augmented Metalloimmunotherapy.

  2024cites this paper
• A novel brain targeting MnOx-Based MI-3 nanoplatform for immunogenic cell death initiated high-efficiency antitumor immunity against orthotopic glioblastoma

  2024cites this paper
• Recent Biomaterial-Assisted Approaches for Immunotherapeutic Inhibition of Cancer Recurrence.

  2024cites this paper
• A1-reprogrammed mesenchymal stromal cells prime potent antitumoral responses

  2024cites this paper
• Polyethylenimine-Coated Pt–Mn Nanostructures for Synergistic Photodynamic/Photothermal/Chemodynamic Tumor Therapy

  2024cites this paper
• Development and Clinical Applications of Therapeutic Cancer Vaccines with Individualized and Shared Neoantigens

  2024cites this paper
• Unraveling the role of exercise in cancer suppression: insights from a mathematical model

  2024cites this paper
• Into the Future: Fighting Melanoma with Immunity

  2024cites this paper
• Cancer Vaccines in the Immunotherapy Era: Promise and Potential

  2023cites this paper
• Regulation of Antigen‐Specific Immunotherapy with Nanomaterials

  2023cites this paper
• Harnessing allogeneic CD4+ T cells to reinvigorate host endogenous antitumor immunity

  2023cites this paper
• CD8+ T cells in the cancer-immunity cycle.

  2023cites this paper
• Advances in Cancer Vaccine Research.

  2023cites this paper
• Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model.

  2023cites this paper
• Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer

  2023influential citation